Add Company
Join Now

Immunophotonics Revenue and Competitors

License our Company Data API

Location

N/A

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Immunophotonics's estimated annual revenue is currently $1.9M per year.(i)
  • Immunophotonics's estimated revenue per employee is $100,500

Employee Data

  • Immunophotonics has 19 Employees.(i)
  • Immunophotonics grew their employee count by 58% last year.

Immunophotonics's People

NameTitleEmail/Phone
1
CEO & Co-FounderReveal Email/Phone
2
VP International Business DevelopmentReveal Email/Phone
3
SVP Science & ResearchReveal Email/Phone
4
VP Regulatory & Clinical AffairsReveal Email/Phone
5
VP Business Development (Immunophotonics, Inc.) Managing Director (IPS Biopharma AG)Reveal Email/Phone
6
Director Clinical OperationsReveal Email/Phone
7
Chief Drug Development OfficerReveal Email/Phone
8
Chief Scientific OfficerReveal Email/Phone
9
General Counsel and Director OperationsReveal Email/Phone
10
President, Chief Innovation Officer & Co-FounderReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$2720.7M84607%N/AN/A
#2
$13.5M673%N/AN/A
#3
$9.2M46-4%N/AN/A
#4
$19.9M9960%N/AN/A
#5
$48.4M24111%N/AN/A
#6
$1.9M1958%N/AN/A
#7
$6M30-9%N/AN/A
#8
$13.1M6512%N/AN/A
#9
$1137.5M35373%$97MN/A
#10
$18.5M92-13%N/AN/A
Add Company

What Is Immunophotonics?

Immunophotonics is a privately owned clinical stage biotech that has discovered a novel and simple approach to achieve patient-specific anticancer immunity. The company is currently developing its first asset, the immune-modulating proprietary carbohydrate polymer IP-001 for the treatment of solid tumor cancers. IP-001 has unique physio-chemical and immunological properties that allows it to ignite a systemically active cancer immunotherapy from a routine tumor ablation; a minimal invasive intervention that destroys tumors and in doing so liberates tumor antigens. IP-001 enhances interactions of tumor antigens with the immune system, improves the motility of tumor infiltrating T cells, promotes their surveillance of tumor tissue and can generate long-term protective immunity.

keywords:N/A

N/A

Total Funding

19

Number of Employees

$1.9M

Revenue (est)

58%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$1.7M190%N/A
#2
$1.7M1912%N/A
#3
$1.7M19-59%N/A
#4
$2.4M19-5%N/A
#5
$2.9M20-31%N/A